Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma

The efficacy of sorafenib in combination with transarterial chemoembolization (TACE) or multiple-line therapies in patients with advanced hepatocellular carcinoma (HCC) remains unclear. This study aimed to investigate the overall survival (OS) of patients with advanced HCC in response to different c...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Medicine (Baltimore)
Autores principales: Hsiao, Pojen, Hsieh, Kun-Chou, Chen, Yaw-Sen, Hsu, Chia-Chang, Lo, Gin-Ho, Li, Yu-Chan, Hsieh, Pei-Min, Lin, Hung-Yu, Wu, Tsung-Chin, Yeh, Jen-Hao, Lin, Chih-Wen
Formato: Artigo
Lenguaje:Inglês
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6636964/
https://ncbi.nlm.nih.gov/pubmed/31232945
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000016074
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares